Follow
Sunder Mudaliar
Sunder Mudaliar
Verified email at vapop.ucsd.edu - Homepage
Title
Cited by
Cited by
Year
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 121-130, 2019
14862019
Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro
JW Kolaczynski, MR Nyce, RV Considine, G Boden, JJ Nolan, R Henry, ...
Diabetes 45 (5), 699-701, 1996
11301996
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ...
Gastroenterology 145 (3), 574-582. e1, 2013
8862013
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
FL Greenway, K Fujioka, RA Plodkowski, S Mudaliar, M Guttadauria, ...
The Lancet 376 (9741), 595-605, 2010
8352010
Pioglitazone for diabetes prevention in impaired glucose tolerance
RA DeFronzo, D Tripathy, DC Schwenke, MA Banerji, GA Bray, ...
New England Journal of Medicine 364 (12), 1104-1115, 2011
7172011
Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis
S Mudaliar, S Alloju, RR Henry
Diabetes care 39 (7), 1115-1122, 2016
5542016
Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.
SE Nikoulina, TP Ciaraldi, S Mudaliar, P Mohideen, L Carter, RR Henry
Diabetes 49 (2), 263-271, 2000
4542000
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 131-138, 2019
3602019
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
P Raskin, BW Bode, JB Marks, IB Hirsch, RL Weinstein, JB McGill, ...
Diabetes care 26 (9), 2598-2603, 2003
3462003
New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers
S Mudaliar, RR Henry
Annual review of medicine 52 (1), 239-257, 2001
3432001
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
SR Mudaliar, FA Lindberg, M Joyce, P Beerdsen, P Strange, A Lin, ...
Diabetes care 22 (9), 1501-1506, 1999
3381999
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy
SA Phillips, TP Ciaraldi, APS Kong, R Bandukwala, V Aroda, L Carter, ...
Diabetes 52 (3), 667-674, 2003
3232003
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized …
D Polidori, S Sha, S Mudaliar, TP Ciaraldi, A Ghosh, N Vaccaro, K Farrell, ...
Diabetes care 36 (8), 2154-2161, 2013
3032013
Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise
RS Richardson, H Wagner, SRD Mudaliar, R Henry, EA Noyszewski, ...
American Journal of Physiology-Heart and Circulatory Physiology 277 (6 …, 1999
2821999
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II …
RR Henry, AM Lincoff, S Mudaliar, M Rabbia, C Chognot, M Herz
The Lancet 374 (9684), 126-135, 2009
2562009
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes
NV Chu, APS Kong, DD Kim, D Armstrong, S Baxi, R Deutsch, M Caulfield, ...
Diabetes Care 25 (3), 542-549, 2002
2512002
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study
RR Henry, J Rosenstock, S Edelman, S Mudaliar, AG Chalamandaris, ...
Diabetes care 38 (3), 412-419, 2015
2392015
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle
SE Nikoulina, TP Ciaraldi, S Mudaliar, L Carter, K Johnson, RR Henry
Diabetes 51 (7), 2190-2198, 2002
2292002
Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action
M Loviscach, N Rehman, L Carter, S Mudaliar, P Mohadeen, TP Ciaraldi, ...
Diabetologia 43 (3), 304-311, 2000
2262000
Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside
S Mudaliar, D Polidori, B Zambrowicz, RR Henry
Diabetes care 38 (12), 2344-2353, 2015
2192015
The system can't perform the operation now. Try again later.
Articles 1–20